| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H25N5O4 |
| Molecular Weight | 363.4115 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N2C=NC3=C2N=CN=C3NC4CCCCC4
InChI
InChIKey=JAKAFSGZUXCHLF-LSCFUAHRSA-N
InChI=1S/C17H25N5O4/c1-25-14-13(24)11(7-23)26-17(14)22-9-20-12-15(18-8-19-16(12)22)21-10-5-3-2-4-6-10/h8-11,13-14,17,23-24H,2-7H2,1H3,(H,18,19,21)/t11-,13-,14-,17-/m1/s1
SDZ-WAG-994 is a potent and selective A1 receptor agonist, discovered by Sandoz. SDZ-WAG-994 was able to induce a dose-related and sustained fall in blood pressure and heart rate in spontaneously hypertensive rats. The compound was investigated in patients with heart failure symptoms and moderate left ventricular systolic dysfunction, where it produced no effect. In patients with patients with permanent atrial fibrillation, SDZ-WAG-994 was able to limit the increase in mean heart rate during exercise. The compound was also tested for treatment of postoperative dental pain, but for all efficacy measures, SDZ-WAG-994 was not significantly different from placebo.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
In a multicenter, double-blind, randomized, placebo-controlled, parallel group study, patients with permanent atrial fibrillation received 2 mg SDZWAG994 orally.
Route of Administration:
Oral
In vitro efficacy of SDZ-WAG-994 was measured by its ability to stimulate adenylate cyclase activity in rat adipocyte membranes. adipocytes from rat epididymal fat pads were homogenized, and adenylate cyclase activity was measured by the formation of [32P]cAMP from [32P]ATP. pEC50 for SDZ-WAG-994 was 6.4.
SUBSTANCE RECORD
